Last reviewed · How we verify
addition of rituximab if recurrence
addition of rituximab if recurrence is a Small molecule drug developed by Fondation Ophtalmologique Adolphe de Rothschild. It is currently in Phase 3 development.
At a glance
| Generic name | addition of rituximab if recurrence |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- CARv3-TEAM-E T Cells in Glioblastoma (PHASE1)
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (PHASE1, PHASE2)
- Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) (PHASE2)
- Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. (PHASE3)
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (PHASE1)
- Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (PHASE2)
- Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma (PHASE2)
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- addition of rituximab if recurrence CI brief — competitive landscape report
- addition of rituximab if recurrence updates RSS · CI watch RSS
- Fondation Ophtalmologique Adolphe de Rothschild portfolio CI
Frequently asked questions about addition of rituximab if recurrence
What is addition of rituximab if recurrence?
addition of rituximab if recurrence is a Small molecule drug developed by Fondation Ophtalmologique Adolphe de Rothschild.
Who makes addition of rituximab if recurrence?
addition of rituximab if recurrence is developed by Fondation Ophtalmologique Adolphe de Rothschild (see full Fondation Ophtalmologique Adolphe de Rothschild pipeline at /company/fondation-ophtalmologique-adolphe-de-rothschild).
What development phase is addition of rituximab if recurrence in?
addition of rituximab if recurrence is in Phase 3.